Immunohistochemical staining of CD61/Platelet Glycoprotein IIIa  of human FFPE tissue followed by incubation with HRP labeled secondary and development with DAB substrate.

CD61/Platelet Glycoprotein IIIa [Y2/51] Antibody (cGMP).

$ 135.00$ 515.00
Please Select Product Options Below To View The Catalog Number.

SKU: QIVD259
Species: Human
Tested Applications: IHC [IVD]
Available Conjugates:
Isotype: Mouse IgG1, kappa

Product NumberDescriptionPrice
QIVD259-0.1ml Size: 0.1 ml, Format: Concentrate $ 135.00
QIVD259-0.5ml Size: 0.5 ml, Format: Concentrate $ 305.00
QIVD259-1ml Size: 1 ml, Format: Concentrate $ 515.00
Shipping Information
In Stock
Flat Rate Shipping Anywhere in the US: $45
Datasheets and Documentation
Product Datasheet
Certificate of Analysis and Tags (Coming Soon)
Lot Number:

Expiration Date:

Concentration (Write Lyophilized if Lyophilized):

Reconsitution Instructions (Leave Blank if Liquid):

Manufacture Date:

Purity:

Bioactivity (test results eg. IU/ml):


SKU: QIVD259-0.1ml
CD61/Platelet Glycoprotein IIIa General Information
Alternate Names
Molecular Weight
87.1 kDa
Chromosomal Location
q21.32 [chr: 17] [chr_start: 47253846] [chr_end: 47311816] [strand: 1]
Curated Database and Bioinformatic Data
Gene SymbolITGB3
Entrez Gene ID3690
RefSeq Protein Accession(s)NP_000203
RefSeq mRNA Accession(s); NM_000212
RefSeq Genomic Accession(s)NC_000017; NG_008332
UniProt ID(s)P05106
PharmGKB ID(s)PA205
KEGG Gene ID(s)hsa:3690
Associated Diseases (KEGG IDs)Glanzmann thrombasthenia (GT) [MIM:273800]: A common inherited disease of platelet aggregation. It is characterized by mucocutaneous bleeding of mild-to-moderate severity. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb-IIIa complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the GPIIb-IIIa complex at reduced levels, have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. {ECO:0000269|PubMed:10233432, ECO:0000269|PubMed:11588040, ECO:0000269|PubMed:11897046, ECO:0000269|PubMed:12083483, ECO:0000269|PubMed:12353082, ECO:0000269|PubMed:1371279, ECO:0000269|PubMed:1438206, ECO:0000269|PubMed:15583747, ECO:0000269|PubMed:15634267, ECO:0000269|PubMed:15748237, ECO:0000269|PubMed:1602006, ECO:0000269|PubMed:20020534, ECO:0000269|PubMed:2392682, ECO:0000269|PubMed:8781422, ECO:0000269|PubMed:9215749, ECO:0000269|PubMed:9376589, ECO:0000269|PubMed:9684783, ECO:0000269|PubMed:9790984}. The disease is caused by mutations affecting the gene represented in this entry.; Bleeding disorder, platelet-type 16 (BDPLT16) [MIM:187800]: An autosomal dominant form of congenital macrothrombocytopenia associated with platelet anisocytosis. It is a disorder of platelet production. Affected individuals may have no or only mildly increased bleeding tendency. In vitro studies show mild platelet functional abnormalities. {ECO:0000269|PubMed:18065693}. The disease is caused by mutations affecting the gene represented in this entry.
General Description of CD61/Platelet Glycoprotein IIIa .
This antibody recognizes a glycoprotein of 110 kDa molecular weight present on human platelets and also reacts with megakaryocytes and megakaryoblasts. The antigen is also present on endothelium and osteoclasts. The glycoprotein IIIa molecule produced by endothelium cells is identical in sequence to platelet glycoprotein IIIa.

Antibody (Suitable for clinical applications)

Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
Specification Recommendation
Recommended Dilution (Conc) 1:25-1:50
Pretreatment HistoZyme
Incubation Parameters 30 min at Room Temperature

Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.

Clonality: Monoclonal
Anti-CD61/Platelet Glycoprotein IIIa Antibody Clone: Y2/51
Host and Isotype: Mouse IgG1, kappa
Recommended Positive Control Sample: Tonsil
Cellular Localization of Antibody Y2/51 Staining: Cell membrane
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: BALB/C mice were immunized with PHA-stimulated human mononuclear cells.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.

CD61/Platelet Glycoprotein IIIa Information for Pathologists

Limitations and Warranty

This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.

There are no reviews yet.

Be the first to review “CD61/Platelet Glycoprotein IIIa [Y2/51] Antibody (cGMP).”

Your email address will not be published. Required fields are marked *

Share a Protocol (View Reviewed Protocols Below)

Protocol Title

Materials

Methods

Notes


  protocol submission gif
enQuire Bio, LLC   8420 S Continental Divide Rd, #202   Littleton, CO 80127
Phone: 1-855-344-1400 | enquire@enquirebio.com | Fax: 1-720-897-3730
Customer Service Available M-F 8AM-6PM MST or 24/7 Via Email

CD61/Platelet Glycoprotein IIIa [Y2/51] Antibody (cGMP).